CD99 is a long known leukocyte antigen that does not belong to any of the known protein families. It was recently found on endothelial cells where it mediates transendothelial migration of human monocytes and lymphocyte recruitment into inflamed skin in the mouse.
Introduction
Leukocytes are recruited into inflamed tissue via endothelial adhesion molecules and chemoattractants [1] [2] [3] [4] . Upon docking to the endothelial surface, which is mediated mainly via selectins and leukocyte integrins, leukocytes transmigrate through the vessel wall, a process called diapedesis 5, 6 . Leukocytes have been reported to traverse the endothelial cell layer either on a transcellular or a paracellular, junctional route 7, 8 . Almost all known endothelial membrane and adhesion molecules that participate in the diapedesis process are located at endothelial cell contacts and therefore are likely to participate in the junctional migration of leukocytes.
VE-cadherin represents a barrier on this route, since adhesion-blocking antibodies against VE-cadherin accelerate recruitment of leukocytes into inflamed tissue 9 . In contrast to VE-cadherin, all other endothelial cell contact proteins assist in the diapedesis process. All of these proteins, except one, are members of the immunoglobulin supergene family (Ig-SF), such as platelet-endothelial cell adhesion molecule (PECAM)-1 10, 11 , members of the junctional adhesion molecule (JAM) family [12] [13] [14] , endothelial cell-selective adhesion molecule (ESAM) 15 , intercellular adhesion molecule (ICAM)-2 16 and polyo virus receptor (PVR) 17 , a member of the nectin family. It is not yet known how they function in detail and it will be a challenging goal for the future to elucidate potential cascades and the interplay of these endothelial cell contact proteins during leukocyte diapedesis.
One of the most recently identified proteins participating in leukocyte diapedesis is CD99, a long known leukocyte surface antigen, which was found to be expressed at endothelial cell contacts and to participate in the in vitro transmigration of human monocytes through monolayers of human endothelial cells 18 . That CD99 is indeed relevant for leukocyte extravasation in vivo was demonstrated in the mouse. Antibodies against mouse CD99
inhibited the recruitment of lymphocytes into inflamed sites of the skin 19 . Whether CD99
would be relevant for the extravasation of myeloid cells in vivo has not yet been analyzed.
CD99 is a rather small membrane protein with a highly O-glycosylated extracellular part comprising only about 100 amino acids. Based on its primary structure it is not related to any known protein family. Three other genes have been described of which two are mapping in the vicinity of the CD99 gene in the human genome and displaying moderate sequence homology to CD99. One of them (MIC2R) is a pseudogene, the second, PBDX, codes for an erythrocyte cell surface antigen (Xga) of unknown function. The third related gene coding for a protein of unknown function was recently cloned in various species 20 . Sequencing revealed
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From a homology of not more than 32% amino acid identity between this gene and CD99 in the mouse. Based on in situ hybridizations the mRNA seems to be widely distributed, with prominent expression on neuronal cells, choroid plexus, sertoli cells, and granulose and theca cells of the ovary 20 . Although no studies have been performed that would attribute any function to the corresponding protein, and expression on leukocytes has not been analyzed, it was tentatively named CD99 antigen like-2 (CD99L2).
Here we have analyzed whether CD99L2 would indeed be functionally related to CD99 and whether it would be relevant for the process of leukocyte extravasation. We generated antibodies against mouse CD99L2 with which we found that this antigen is expressed on neutrophils and lymphocytes as well as on endothelium in various tissues.
Despite its strong expression on lymphocytes and in contrast to CD99, CD99L2 was not involved in the recruitment of lymphocytes into inflamed skin. However, in two different inflammation models, antibodies against CD99L2 inhibited the extravasation of neutrophils.
Intravital and electron microscopy allowed to demonstrate that CD99L2 was not relevant for the contact formation between leukocytes and endothelium, but rather for the actual transmigration step. In addition, CD99 was also found to participate in neutrophil diapedesis in vivo. Our results establish CD99L2 as a new endothelial surface protein that participates in the extravasation and diapedesis of neutrophils.
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Materials and Methods

Cell culture
The following cells were propagated as described: Proteinlipid protein (PLP)-specific T H1 memory /effector T cell line SJL.PLP7 21 polyclonal rabbit antibodies against mouse CD99 and mouse ESAM were generated as described previously 25 . Monoclonal antibodies were purified from hybridoma supernatants:
anti-mouse ICAM-1 (YN1/1.7, rat IgG-2b, from ATCC) 26 ; anti mouse L-selectin (MEL14, from ATCC); anti-mouse P-selectin (RB40.34, rat IgG1); anti mouse PECAM-1 (1G5.1, rat
IgG2b; 5D2.6, rat IgG2a) (both unpublished). Purchased antibodies: anti-LFA-1 (BD Pharmingen). Cy3-conjugated anti-rabbit IgG, PE-conjugated anti-rabbit IgG, peroxidaseconjugated anti-rabbit IgG (Dianova, Hamburg, Germany); FITC-labeled and peroxidaselabeled polyclonal antibodies to rabbit IgG F(ab') 2 (Acris, Hiddenhausen, Germany).
Immunofluorescence staining and western blots were done as described 25 .
Glycosidase treatment
3 µg of CD99L2-Fc fusion protein as digested in 150 µl of 25 mM NaH 2 PO 4 , pH6.0 for 18 h at 37°C. The reaction was stopped by boiling in SDS-PAGE sample buffer and 100 ng of the reaction mixture were electrophoresed, and detected by immunoblotting with peroxidase conjugated anti-human IgG followed by ECL.
Cloning of mouse CD99L2 isoforms
For generation of a mouse CD99L2-Fc fusion protein, total cellular RNA was isolated from RT-PCR was performed with total cell RNA from mouse endothelioma cells bEnd.5 and from HUVEC.
Immunohistochemistry and flow cytometry
Animals were anaesthetized using Isoflurene anesthesia (Abbott, Wiesbaden, Germany), and were perfused with 10 ml PBS through the left ventricle of the heart. Tissue was removed, embedded in Tissue-tec, (OCT, Miles Inc., Giessen, Germany), and snap-frozen. Cryostat sections (6 µm) were stained as described 27 . Flow cytometry was done as described 28 .
Aggregation assay
Our assay was modified from a previously described method 29 and was done as described 19 .
Quantification of aggregation was estimated by the following formula: % aggregation = (N 0 -N t )/N 0 x 100, where N t is the total number of particles at the incubation time t, and N 0 is the 
Adhesion assay
Adhesion assays were done as described 19 , except for that PMNs were used instead of lymphocytes.
Preparation of mouse bone marrow neutrophils
NMRI mice (Harlan-Winkelmann, Borchen, Germany) were sacrificed, femurs and tibias were cut out and muscles were removed. Bones were placed in Ca
2+
/Mg 2+ -free HBSS (HBSS-/-) to prevent dry-out. The ends of the bones were cut and the bone marrow was flushed into a 50ml tube with HBSS-/-(Gibco, Eggenstein, Germany) using a short (5/8'') 25 G needle and a 2 ml syringe. Larger bone marrow pieces were disaggregated using a plastic pipette and a mesh (70 µm). The cell suspension was centrifuged (300 x g, 10 min) and the pellet was resuspended in 1 ml HBSS-/-. The cell suspension was then added on top of a 10 ml tube containing 4ml Histopaque 1119 an 4 ml Histopaque 1077 (Sigma-Aldrich, Steinheim, Germany). After centrifugation for 30 min at 700 g (brake off), PMN-containing cell layer was collected and washed two times with HBSS-/-.
Transmigration assay
Transendothelial migration of SJL.PLP7 and PMNs was performed as described 19, 23 . 5x 10 4 bEnd.5 cells/well of 6.5 mm Transwells (costar, Bodenheim, Germany) were grown for two days for each assay. For assays with PMNs, 5x10 5 PMNs were added per transwell and chemoattraction was done with 40 ng/ml KC in the bottom chamber. Migrated leukocytes were collected for cell counting (CASY, Schärfe-System, Reutlingen, Germany). Confluency of the endothelial monolayer was confirmed after each assay on formalin fixed and 2.6%
Giemsa stained inserts.
Contact hypersensitivity and T cell immigration into inflamed skin
Experiments were done as described 19 .
Thioglycollate-induced peritonitis assay
For each assay 5 female Balb/c mice 8-12 weeks were used. Thioglycollate-induced peritonitis assays (induced by 3% sterile thioglycollate broth) were essentially performed as described 28 , except for the peritoneal lavage was done with 20 mL PBS containing 3 mM EDTA, total cell counts were determined with a cell counter and the percentage of neutrophils was determined by flow cytometry (FACS Calibur, BD Heidelberg) using the mAb RB6-8C5 against Ly-6G and Ly6C (Gr-1).
Intravital microscopy
Surgical preparation of cremaster muscles and intravital microscopy were essentially done as described 15, 30 . 
Electron microscopy
Four hours after inflammatory stimulation and antibody injection (as described above) the cremaster muscle was dissected and prepared for electron microscopy as described for other tissues before 31 . For each vessel, the number of leukocytes in each of the following positions was determined: A: within lumen of vessel, B: crossing the endothelium, C: between endothelium and basement membrane/pericyte; D: outside the vessel but within 50 µm of it.
The fraction of leukocytes that were diapedesing, but were still inside the basement membrane or pericyte layer was calculated by the equation C/C+D. For each antibody type, 32-52 vessels of 2-3 mice were evaluated.
Results
Generation and characterization of specific antibodies against CD99L2
In the course of cloning the mouse ortholog of human CD99 19 , we found additional clones in the mouse gene data base that coded for a CD99 related protein (MIC2-like1), for which later the name CD99L2 has been suggested 20 . Based on the sequence of clone NM_138309 we designed primers with which we cloned two RT-PCR products of 660 bp and 729 bp from poly A + -RNA of mouse spleen. Sequencing the smaller product revealed full match with clone NM_138309. The larger product was identical except for an additional 69 bp insertion.
During the course of our project this larger form has been described in the gene data base and the inserted sequence has been designated as exon 3A 20 .
In order to study the CD99L2 protein, we generated polyclonal antibodies against a mouse CD99L2-Fc fusion protein containing the complete extracellular part of the shorter splice variant of CD99L2 (E3-E4 form) fused to the Fc part of human IgG 1 . Polyclonal antibodies against mouse CD99 had been raised against a CD99-Fc fusion protein and were described before 19 . Since mouse CD99L2 and CD99 show 32% amino acid identity, we tested our affinity purified antibodies against CD99L2 and CD99 for cross-reactivity. The antibody (Fig. 1B) . Thus, our affinity-purified antibodies against CD99L2 and CD99 are strictly specific for their respective antigen.
CD99L2 is expressed on endothelial cells
To characterize the proteins corresponding to the two splice variants of CD99L2, CHO cells transfected with the short (CD99L2 S ) and the long (CD99L2 L ) splicing variant of CD99L2
were analyzed by immunoblotting. This revealed that CD99L2 S gave rise to a 40kD/37kD doublet whereas the longer form was recognized as a 56kD/40kD doublet ( Fig. 2A) . (Fig. 2B ).
In immunoblots of the mouse endothelioma cell line bEnd.5, antibodies against CD99L2 recognized a major band at 56 kD and a minor band at 40 kD ( Fig. 2A, lane 8) . To determine whether these two bands could indeed represent the two splice variants we performed RT-PCR experiments with total RNA from bEnd.5 cells. As shown in Fig. 2C , two cDNA fragments were generated with the higher molecular weight form being the dominant one. The large splice variant was also the dominant one in HUVEC, besides two minor smaller variants (Fig. 2C ). Sequencing revealed that these products originated from the known splice variants. Thus, endothelial cells express mainly the larger splice variant of CD99L2, and only very small amounts of the smaller ones.
To examine the subcellular distribution of CD99L2, unfixed bEnd.5 endothelioma cells were incubated at 4°C with anti-CD99L2 antibodies, washed, fixed and then stained with secondary antibodies. CD99L2 staining was found to be concentrated at cell-cell contacts of cultured endothelial cells, although it was also found on the entire surface of the cells (Fig.   2D ). On cryosections of various tissues such as heart, kidney and liver, antibodies against mouse CD99L2 stained endothelial cells (Fig. 2E ) similarly to antibodies against CD99 which were used for controls.
CD99L2 is expressed on leukocytes
Cell surface expression of CD99L2 on mouse leukocytes was analyzed by flow cytometry. T and B cells as well as neutrophils from peripheral blood were strongly positive for CD99L2 and the expression levels were comparable to those of CD99 (Fig. 3) . Analyzing leukocytes that we routinely use in in vitro transendothelial migration assays, we found that the T cell line SJL.PLP7 expressed CD99L2 at similar levels as primary lymphocytes, whereas bone marrow derived neutrophils expressed almost undetectable levels of CD99L2 and well detectable levels of CD99. The drastic difference between the CD99L2-expression levels on peripheral and bone marrow derived neutrophils makes CD99L2 one of very few antigens induced with neutrophil maturation. .
CD99L2 supports cell aggregation of transfected cells
Surprisingly, and in clear contrast to CD99, antibodies against CD99L2 could not block CD99L2-dependent cell aggregation, whereas anti-CD99 antibodies, as we showed before, efficiently blocked aggregation of CD99 transfected cells (Fig. 4B) . Thus, either our anti CD99L2 antibodies are not able to block a potential adhesive function of CD99L2, or CD99L2 is stimulating the adhesive function of other adhesion molecules.
It is unlikely that cell aggregation was dependent on homophilic CD99L2 interactions, since 
CD99L2, in contrast to CD99, is not required for lymphocyte extravasation
We have recently found that mouse CD99 is required for the migration of T cells through the monolayer of endothelial cells, as was shown by blocking transmigration of SJL/PLP7 T cells through the monolayer of bEnd.5 endothelial cells with anti-CD99 antibodies 19 . Since both cell types express CD99L2 (as described above), we tested anti-CD99L2 antibodies in this assay. As shown in Fig. 5A , no inhibitory effect of the antibodies was detected, whereas anti CD99 and anti ICAM-1 antibodies, as expected, efficiently inhibited T cell transmigration.
The assays were performed for 30 min with the antibodies present during the assay and in the presence of the chemoattractant SDF-1 in the lower chamber. Comparable results were obtained when transmigration was allowed for 2 h in the absence of a chemokine (not shown).
Despite this lack of inhibition, we tested whether these antibodies would affect the recruitment of T cells into inflamed areas of the mouse skin in a typical delayed type hypersensitivity (DTH) model. In vivo activated T cells were isolated from lymph nodes of were sacrificed 15 h later and radioactivity in the right ear was determined. As shown in Fig   5B , T cell recruitment was only inhibited with antibodies against E-and P-selectin, whereas the antibodies against CD99L2 had no effect. Thus, CD99L2 seems to differ considerably from CD99 and only antibodies against the latter interfere with lymphocyte extravasation.
CD99L2 as well as CD99 are involved in the transendothelial migration of neutrophils in vitro
Since human CD99 had been reported to be involved in the transmigration of human monocytes 18 , we tested, whether mouse CD99 or CD99L2 are relevant for the transendothelial migration of mouse myeloid cells. Due to the low yields of mouse neutrophils that can be obtained from blood, we used neutrophils isolated from bone marrow, although they expressed only low amounts of CD99 and almost undetectable levels of CD99L2.
Remarkably and in contrast to the situation with lymphocytes, antibodies against each antigen, CD99 as well as CD99L2, clearly inhibited transmigration of neutrophils (Fig. 6A) .
A similar result was found for F(ab') 2 fragments of both antibody preparations, excluding potential problems with myeloid Fc-receptors (Fig. 6A ). This establishes for the first time CD99 and CD99L2 as molecules involved in the transendothelial migration of mouse neutrophils. In addition, it demonstrates that our anti CD99L2 antibodies are indeed able to block a function of this antigen.
The low expression of CD99 and the hardly detectable expression of CD99L2 on bone marrow derived neutrophils already suggested that the antibodies affected transmigration via binding to the endothelial antigens. To test this more directly, we pre-incubated bEnd.5 cells with either anti CD99 or anti CD99L2 antibodies and washed them away prior to the assay.
We found that this treatment reduced neutrophil transmigration almost as efficiently as when antibodies were still present during the assay (Fig. 6B) , demonstrating that indeed each of the two antigens act on the endothelial side. Pre-incubating only neutrophils with antibodies prior to the assay did not yield conclusive results, since the test antibodies as well as negative control antibodies from the pre-immune sera inhibited transmigration, possibly due to unspecificly activating neutrophils via Fc-receptors. In order to avoid this problem, we preincubated neutrophils with F(ab') 2 -fragments of anti CD99, anti CD99L2 and pre-immune
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To determine whether CD99 and CD99L2 act in independent pathways, we tested whether F(ab') 2 -fragments of antibodies against each antigen would have additive inhibitory effects. As shown in Fig. 6D , both types of F(ab') 2 -fragments together had no stronger inhibitory effect than F(ab') 2 -fragments against each antigen alone. We conclude that the CD99-independent extravasation of neutrophils is also CD99L2-independent.
In order to distinguish whether any of the two antigens would participate in neutrophil transmigration via mediating adhesion of neutrophils to endothelial cells or via participating in the transendothelial migration step, we tested whether the antibodies would inhibit adhesion of neutrophils to bEnd.5 cells. No such inhibitory effect was found (Fig. 6E) . We conclude that CD99 as well as CD99L2 on endothelial cells are involved in the migration of neutrophils through endothelial cell layers.
CD99 and CD99L2 participate in the migration of neutrophils into inflamed peritoneum.
Chemically induced peritonitis is a well-characterized model to study neutrophil recruitment into sites of acute inflammation in vivo. We tested whether i.v. injection of either anti CD99 or anti CD99L2 antibodies immediately before i.p. injection of thioglycollate would affect the recruitment of neutrophils into the peritoneum within a 4 h period after stimulation. We found that antibodies against CD99 reduced neutrophil accumulation by 59% (±12%), whereas anti CD99L2 antibodies inhibited by 69% (±5%) when compared with negative control antibodies from the pre-immune sera (Fig. 7A ). Combined treatment with anti L-and anti P-selectin antibodies blocked neutrophil recruitment by more than 85%. Injection of PBS without antibodies gave similar results as negative control antibodies (not shown). To exclude the possibility that interactions with Fc-receptors or complement would interfere with our results, we also tested F(ab') 2 -fragments. As shown in Fig.7A , F(ab') 2 -fragments of anti CD99 as well as of CD99L2 antibodies reduced neutrophil recruitment into inflamed peritoneum significantly, although the inhibitory effect was less pronounced compared to the decrease observed with intact antibodies. 
Antibodies against CD99 or CD99L2 inhibit neutrophil extravasation in vivo at the level of transmigration
To clarify in vivo at which step during the process of leukocyte extravasation CD99L2 and CD99 are involved, we visualized the process in the cremaster muscle using intravital nearinfrared reflected light oblique transillumination microscopy 30 . Under the experimental conditions used, the vast majority (more than 80%) of extravasating leukocytes are neutrophils 15 . Mice were intravenously injected with antibodies and stimulated intrascrotally with IL-1β for 4 h prior to microscopic analysis. As can be seen in (Fig. 7B) , neither anti CD99 nor anti CD99L2 antibodies affected rolling or adhesion of leukocytes in the observed cremaster venules. Instead, antibodies against both antigens significantly reduced the number of extravasated neutrophils accumulating in the observation area. Similar results were obtained with F(ab') 2 -fragments (Fig. 7B) . Thus, CD99 as well as CD99L2 are involved in vivo in the diapedesis of neutrophils.
To determine at which step of the diapedesis process leukocytes are arrested by the antibodies against CD99L2, the cremaster tissue was analyzed by electron microscopy.
Animals treated with antibodies against CD99L2 or against PECAM-1 had significantly larger numbers of leukocytes trapped between the endothelium and the basement membrane/ pericyte layer than animals treated with control antibodies (Fig. 7C and D) . Independent of the type of antibody used, the number of leukocytes trapped between endothelial cells Importantly, we could demonstrate by electron microscopy that anti-CD99L2
antibodies trap neutrophils between the basal side of the endothelium and the basement membrane/ pericyte layer similarly as anti PECAM-1 antibodies. This confirms other studies for PECAM-1 33, 34 and establishes CD99L2 as the second endothelial cell contact protein for which it has been determined in vivo at which step during diapedesis it is required.
Despite the many similarities, CD99 and CD99L2 differ in important aspects. Most importantly, they participate in the extravasation of different repertoires of leukocytes.
Whereas both proteins mediate the extravasation of neutrophils, only CD99 is relevant for the extravasation of lymphocytes, despite strong expression of CD99L2 on lymphocytes. The possibility that CD99L2 might even participate in lymphocyte extravasation and that our antibodies are merely unable to block this process is unlikely, although cannot be ruled out.
It has been suggested that CD99 may participate in lymphocyte diapedesis via homophilic interactions. This is based on the findings that transmigration required CD99 on lymphocytes and on endothelial cells and that CD99 supports homotypic cell aggregation of transfected cells 19 . Similar results have been demonstrated for human CD99 and its role in 18 . Obviously CD99L2 on lymphocytes is not able to function in the same way, since it is not involved in lymphocyte diapedesis although it is present on the surface of both cell types.
Interestingly, neutrophils seem to extravasate in a different way than lymphocytes with respect to the participation of CD99 and CD99L2. Both proteins on endothelial cells are involved in the transendothelial migration of neutrophils, since antibodies against each of the two proteins inhibited transmigration, when incubated with endothelial cells only. It is unlikely that endothelial CD99 or CD99L2 participated in diapedesis by homophilic binding to their respective counterpart on neutrophils since, first, CD99L2 was almost undetectable on bone marrow derived neutrophils and CD99 was only weakly expressed. Second and more importantly, even if the weak expression levels of CD99 and CD99L2 on bone marrow derived neutrophils would have been sufficient to serve as binding partners for endothelial CD99 or CD99L2, it would have been expected that incubating neutrophils with antibodies against CD99 or CD99L2 would have reduced transmigration. Since this was not the case, we conclude that endothelial CD99 and CD99L2 probably can mediate neutrophil transmigration independent of their respective counterparts on the neutrophil surface. However, we cannot exclude that, in addition, CD99 or CD99L2 on peripheral neutrophils could be involved in diapedesis, since both proteins are expressed at much higher levels on these cells than on bone marrow-derived neutrophils. Further investigations are necessary to reveal the mechanisms that enable CD99 and CD99L2 to control and mediate leukocyte diapedesis. Whatever mechanism will be elucidated for CD99 and CD99L2, our present study establishes CD99L2 as a cell surface protein on endothelium that represents a novel target to block infiltration of neutrophils into inflamed tissue. Tissue sections were incubated with first antibodies, followed by washing and incubation with secondary and tertiary reagent. Bar = 70 µm Antibodies remained present during the assay. (B) After pre-incubation of the endothelial cells with the indicated antibodies, the antibodies either remained present during the assay (first four bars) or were washed away before adding the PMNs (indicated by "pre-inc." underneath the last four bars). ***p<0,001 anti-CD99 vs. co-IgG, **p<0,01 anti-CD99L2 vs.
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